|
|
|
Alexander DeLuca, M.D., FASAM |
|
Presentation to the Department of Medicine of
St. Luke’s / Roosevelt Hospital Center, New York City |
|
2/12/2002 |
|
|
|
http://www.doctordeluca.com/ |
|
|
|
|
|
Traditionally, there has been an assumption on
the part of clinicians in the field that these entities are part of a
continuum of illness |
|
We call substance abuse disorders “chronic,
relapsing and progressive” |
|
|
|
We have thought (and taught) that if a person
destined for alcohol dependence had 1-3 alcohol-related problems today,
that number would increase over time |
|
|
|
|
|
Roots not in medicine or psychiatry, but in the
self-help movement as epitomized by Alcoholics Anonymous. |
|
Focus on complete (‘radical’) abstinence |
|
|
|
While the NIH and any textbook will tell you
that the first line treatment for alcohol abuse is decreased alcohol intake
and an attempt to regain control, this is not an option on the menu of the
average treatment center |
|
|
|
|
|
Alcohol abuse is rarely identified and treated
as such except in special populations |
|
If abuse = ‘dependence early on the curve,’ then
the tendency to treat all patients presenting for treatment in the same
setting and with the same modalities is somewhat rational |
|
Controlled drinking and moderation remain highly
contentious concepts within the treatment community |
|
|
|
|
|
Schuckitt, 2001: |
|
Prospective study of over 1300 |
|
DSM-IV diagnosis of alcohol dependence predicts
a chronic disorder with a relatively severe course |
|
DSM-IV diagnosis of abuse predicts a milder,
less persistent disorder that does not usually progress to dependence |
|
Krystal, 2001: |
|
“Our findings do not support the use of
naltrexone for the treatment of… chronic, severe alcohol dependence.” |
|
Sinclair, 2001: |
|
No benefit of NAL over placebo when combined
with support for abstinence. “Naltrexone is most effective when paired with
drinking but ineffective when given during abstinence…” |
|
|
|
|
|
|
|
Krystal ’01: Multi-center DBPC study of NAL as
adjunctive Tx to individual 12-step facilitation therapy and encouragement
to attend AA. |
|
627 vets, almost all male, with chronic, severe
alcohol dependence |
|
Three groups: 12 month NAL daily; 3 months NAL à 9 months placebo;
12 months placebo. |
|
At 13 weeks, no significant difference between
NAL and placebo in days to relapse. At 52 weeks, no differences in % of
drinking days or # drinks per day. |
|
Unfortunately, this lead article in the NEJM
will be misunderstood as proving that ‘NAL doesn’t work,’ which was not
helped, IMO, by the defensive-sounding Fuller / Gordis letter in the same
issue. |
|
|
|
|
|
|
There are two different hypotheses about how
naltrexone (NAL) works in the treatment of alcohol disorders |
|
Abstinence protocol – hypothesis: craving and/or
reinforcing properties of alcohol mediated by opioid system and are blocked
by NAL |
|
Extinction protocol – hypothesis: opioidergic
activity reinforces drinking and NAL blocks the reinforcement |
|
|
|
Type of adjunctive psychosocial treatment |
|
“Supportive” aka 12 Step Facilitation therapy |
|
Cognitive Behavioral Therapy |
|
Coping Skills Therapy is variant most studied in
association with NAL |
|
|
|
|
Balldin ’97 - NAL is effective when paired with
CBT, otherwise not. |
|
|
|
O’Malley ’96 – Relapse to heavy drinking
prevented in Coping Skills group and not in the abstinence oriented
“supportive” psychotherapy group. |
|
|
|
|
|
Sinclair 2000: Review of 8 double blind placebo
controlled studies. Three trials tested NAL in two ways: |
|
1)
‘supportive,’ (abstinence-oriented) psychotherapy |
|
|
|
2) with
therapy acknowledging that relapse occurs and teaching how to cope
including how to control drinking once it has begun |
|
|
|
All found benefits with NAL + Coping Skills;
none with NAL + abstinence |
|
|
|
|
|
Detoxification |
|
|
|
Period of abstinence without medication |
|
Usually one to three weeks |
|
|
|
Naltrexone daily in association with individual
or group psychotherapy |
|
Usually three to six months |
|
Usually 50 mg per day |
|
|
|
Naltrexone discontinued |
|
|
|
|
|
Based on extensive preclinical research using
animal models |
|
Naltrexone causes extinction of alcohol drinking |
|
Naltrexone causes extinction of responding for
alcohol |
|
|
|
Naltrexone is started without requiring prior
detoxification or abstinence |
|
Usually 50 mg daily |
|
|
|
Variant: naltrexone taken only in drinking
situations; drug is carried indefinitely. |
|
|
|
|
|
|
|
|
|
|
|
Used in Volpicelli ’92 and O’Malley ’92 |
|
Double blind, placebo controlled studies of
approximately 100 patients each |
|
Significantly decreased craving, fewer drinking
days, fewer patient meeting relapse criteria, higher abstention rates, of
those who drank – fewer relapsed |
|
|
|
Consequently, similar protocol used in
subsequent clinical trials and in most clinical practice |
|
|
|
|
|
If NAL helps patients abstain longer compared to
placebo, this would justify requirement of detox and abstinence. |
|
|
|
Overwhelmingly, the clinical trial literature
shows no significant difference between NAL and placebo conditions prior to
the onset of drinking |
|
Only study to contrary with significant positive
NAL effect in abstinent condition is Volpicelli ’97 after excluding
non-compliant patients and non-completers. |
|
|
|
Literature generally does demonstrate beneficial
NAL effects after some drinking has resumed |
|
|
|
|
|
|
|
|
Volpicelli ’92: “[NTX Tx] did not appear to
prevent subjects from sampling alcohol…The primary effect…was seen in
patients who drank any alcohol while attending outpatient treatment.” |
|
Moncrieff ’97 on O’Malley ’92: “Two survival
analysis are presented, one with any drinking and one with relapse as the
criterion of failure. The latter but not the former demonstrate significant
overall effect of medication.” |
|
Chick 2000: “[A] statistically significant
advantage in the… time to first drinking, was not seen, although there was
a trend… although patients were advised to abstain, < 20% did so.” |
|
|
|
|
|
With only weak (not statistically significant)
positive effects for NTX demonstrated, can detox and radical abstinence be
justified considering: |
|
The rebound effect, probably secondary to
receptor upregulation by NTX, causing increased drinking after period of
NTX & abstention in animal models |
|
If it is unethical to tell a successfully
abstinent alcoholic to resume drinking, is it not also “… unethical to tell
patients to abstain while on NTX, knowing that they will receive the major
benefits only if they disobey…” |
|
|
|
|
|
|
|
Only a small percentage of problem drinkers seek
help |
|
Understandable fear and loathing of diagnosis
and treatment is likely a significant part of the reason |
|
Presenting for treatment will almost surely net
you a “diagnosis” (label) of “alcoholism” and a prescription for lifelong
radical abstinence |
|
Detoxification can be uncomfortable and
dangerous, and is always expensive |
|
A subset of patients are unable to abstain for
the requisite period prior to NAL initiation and this waiting period is not
supported by research |
|
Many problem drinkers would likely appreciate
the option of controlled drinking and NAL |
|